{
    "nctId": "NCT03221881",
    "briefTitle": "Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx\u00ae) and Paclitaxel in Breast Cancer",
    "officialTitle": "The Effectiveness and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "PCR rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with newly diagnosed breast cancer;\n2. Age \\>18 years;\n3. Eastern Cooperative Group (ECOG) performance status 0-2;\n4. measurable disease (as per radiological imaging); life\n5. expectancy \\>12 months;\n6. adequate haematologic blood profile;\n7. normal liver and kidney function;\n8. adequate cardiac function;\n9. no metastatic disease;\n10. negative pregnancy test (premenopausal women);\n11. signed informed consent.\n\nExclusion Criteria:\n\n1. Level 2 cardiac toxic effects were de\ufb01ned as asymptomatic systolic dysfunction (NYHA class I) or mildly symptomatic heart failure (NYHA class II) ;\n2. Previous treatment for breast cancer, including surgery, radiation, cytotoxic and endocrine treatments (except surgical diagnostic procedures);\n3. Active infection or other serious underlying medical or psychiatric condition which would impair the ability of the patient to receive protocol treatment;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}